Davis Polk advised the joint lead dealer managers in connection with the registered offers by Abbott Laboratories to exchange certain outstanding debt securities of St. Jude Medical, LLC, a wholly owned subsidiary of Abbott, for an aggregate of approximately $2.9 billion of newly issued debt securities of Abbott. The transaction consisted of exchange offers pursuant to which five tranches of newly issued debt securities of Abbott were offered in exchange for five tranches of outstanding debt securities of St. Jude, along with related consent solicitations to amend the indentures governing the outstanding debt securities of St. Jude.

Abbott is a global healthcare company that researches and manufactures a range of medical technologies. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 94,000 people.

The Davis Polk corporate team included partner Deanna L. Kirkpatrick, counsel Jeffrey S. Ramsay and associates Christopher M. Bezeg and Andrew J. Terjesen. Partner Rachel D. Kleinberg and associate Dao Fu provided tax advice. The environmental team included counsel Loyti Cheng and associate Yuko Masunaga. Associates Bonnie Chen and Tilak Koilvaram provided intellectual property and technology advice. Members of the Davis Polk team are based in the New York and Northern California offices. 

Copy link to share post